US phase 3 ASTRA (NCT07368959) will enroll across ~12 sites, randomizing patients to a single intracameral administration of AURN001 combining allogeneic endothelial cells with Y-27632. The primary ...
JACKSON, WI - April 07, 2026 - PRESSADVANTAGE - Nicolet Plastics LLC, a custom injection molding company based in ...
Thompson Rivers University's board has another two months to consider the closure of its long-standing Williams Lake ...
Watching NASA’s Artemis 2 astronauts fly around the Moon and make spaceflight history brought up a lot of emotions—but mostly ...
Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of ...
An NFL writer predicted that the Pittsburgh Steelers would select a game-changing player with the 21st pick who could ...
Vanda Pharma begins Thetis study, a clinical trial of Nereus for prevention of vomiting induced by GLP-1 receptor agonists: Washington Friday, April 10, 2026, 14:00 Hrs [IST] Vand ...
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...
In December, Vanda Pharmaceuticals gained FDA approval for its motion sickness drug Nereus. But a much larger patient population may be in store for the oral therapy as the Washington, D.C.-based ...
Last offseason, the Minnesota Vikings lost starting safety Cam Bynum to the Indianapolis Colts in free agency. The former ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results